World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
133
Citations
88126
World Ranking
2184
National Ranking
1233

A. John Iafrate publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where A. John Iafrate sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 458 publications — 50th percentile

50% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

A. John Iafrate D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where A. John Iafrate sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 133 D-Index — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

A. John Iafrate is affiliated with Harvard University in the United States and has contributed extensively to medical research, with a particular focus on infectious diseases, molecular biology, oncology, and pulmonary medicine. Their work covers several domains, including SARS-CoV-2 and COVID-19 research as well as cancer genomics and diagnostics.

The scientist's research topics prominently include:

  • SARS-CoV-2 and COVID-19 Research
  • Cancer Genomics and Diagnostics
  • COVID-19 Clinical Research Studies
  • Lung Cancer Treatments and Mutations
  • SARS-CoV-2 detection and testing
  • Sarcoma Diagnosis and Treatment
  • Viral gastroenteritis research and epidemiology

Their main fields of study encompass Medicine and Biochemistry, Genetics and Molecular Biology. Subfields address Infectious Diseases, Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, and Cancer Research.

Recent notable publications by A. John Iafrate include:

  • Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity, 2021, Cell
  • mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant, 2022, Cell
  • COVID-19-neutralizing antibodies predict disease severity and survival, 2020, Cell
  • Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients, 2020, Science Immunology
  • Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity, 2021, Cell

A. John Iafrate frequently collaborates with several co-authors, including:

  • Jochen K. Lennerz
  • Vivek Naranbhai
  • Julia Thierauf
  • Wilfredo F. García-Beltrán
  • Alejandro B. Balazs

The scientist's work appears in multiple publication venues, notably:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Cancer Research
  • Cell

Best Publications

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

    Lecia V. Sequist;Belinda A. Waltman;Dora Dias-Santagata;Subba Digumarthy

  • Detection of large-scale variation in the human genome.

    A John Iafrate;Lars Feuk;Miguel N Rivera;Miguel N Rivera;Marc L Listewnik

  • Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

    Alice T. Shaw;Beow Y. Yeap;Mari Mino-Kenudson;Subba R. Digumarthy

  • GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases

    Shengdar Q Tsai;Zongli Zheng;Nhu T Nguyen;Matthew Liebers

  • Detection of Mutations in EGFR in Circulating Lung-Cancer Cells

    Shyamala Maheswaran;Lecia V. Sequist;Sunitha Nagrath;Lindsey Ulkus

  • Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Sai Hong I. Ou;Yung Jue Bang;D. Ross Camidge

  • ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

    Kristin Bergethon;Alice T. Shaw;Sai Hong Ignatius Ou;Ryohei Katayama

  • Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski

  • Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.

    Wilfredo F. Garcia-Beltran;Wilfredo F. Garcia-Beltran;Evan C. Lam;Kerri St. Denis;Adam D. Nitido

  • Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

    D. Ross Camidge;Yung Jue Bang;Eunice L. Kwak;A. John Iafrate

  • Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

    Ryohei Katayama;Alice T. Shaw;Alice T. Shaw;Tahsin M. Khan;Tahsin M. Khan;Mari Mino-Kenudson

  • Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

    Alexa B. Turke;Kreshnik Zejnullahu;Yi Long Wu;Youngchul Song

  • Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

    Justin F. Gainor;Leila Dardaei;Satoshi Yoda;Luc Friboulet

  • Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

    Alice T. Shaw;Beow Y. Yeap;Benjamin J. Solomon;Gregory J. Riely

  • First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

    Lecia V. Sequist;Renato G. Martins;David Spigel;Steven M. Grunberg

  • Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma

    Itay Tirosh;Andrew S. Venteicher;Andrew S. Venteicher;Christine Hebert;Christine Hebert;Leah E. Escalante;Leah E. Escalante

  • Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility

    Min Yu;Min Yu;Aditya Bardia;Nicola Aceto;Francesca Bersani

  • Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq

    Andrew S. Venteicher;Andrew S. Venteicher;Itay Tirosh;Christine Hebert;Christine Hebert;Keren Yizhak;Keren Yizhak

  • Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

    Aaron N. Hata;Matthew J. Niederst;Hannah L. Archibald;Maria Gomez-Caraballo

Frequent Co-Authors

Mari Mino-Kenudson
Mari Mino-Kenudson Harvard University
Alice T. Shaw
Alice T. Shaw Harvard University
Tracy T. Batchelor
Tracy T. Batchelor Brigham and Women's Hospital
Jeffrey W. Clark
Jeffrey W. Clark Harvard University
David N. Louis
David N. Louis Harvard University
Jeffrey A. Engelman
Jeffrey A. Engelman Novartis Institutes for BioMedical Research (NIBR)
Daniel A. Haber
Daniel A. Haber Harvard University
Todd R. Golub
Todd R. Golub Harvard University
Gad Getz
Gad Getz Broad Institute
Lecia V. Sequist
Lecia V. Sequist Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in studying Medicine in the USA but want to explore other healthcare careers, there are several flexible online degree paths to consider. For those who want to become registered nurses but are concerned about entrance exams, consider enrolling in a nursing school that does not require teas test. This can make starting your nursing education more accessible.

Individuals with an interest in the business side of healthcare may pursue an health administration degree. These online programs prepare students for leadership roles in hospitals, clinics, and other healthcare facilities without the commitment of medical school.

For those already holding an associate degree in nursing (ADN), advancing your career is possible through adn to fnp programs. These bridge programs offer a pathway to becoming a Family Nurse Practitioner, expanding both your knowledge and clinical opportunities.

If nutrition and wellness are your passions, consider exploring online nutrition degree programs. These allow students to study the science of healthy living from home, leading to careers in education, consulting, or health advocacy.

Best Scientists Citing A. John Iafrate

Trending Scientists

Recently Published Articles